An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)
Latest Information Update: 15 Dec 2024
Price :
$35 *
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURPASS-SWITCH-2
- Sponsors Eli Lilly and Company
- 22 Jan 2024 Status changed from active, no longer recruiting to completed.
- 14 Sep 2023 Planned End Date changed from 23 Nov 2023 to 2 Nov 2023.
- 14 Sep 2023 Planned primary completion date changed from 23 Nov 2023 to 2 Nov 2023.